MA48751A - Paradigme de traitement pour un traitement combiné d'anticorps anti-cd19 et de venetoclax - Google Patents
Paradigme de traitement pour un traitement combiné d'anticorps anti-cd19 et de venetoclaxInfo
- Publication number
- MA48751A MA48751A MA048751A MA48751A MA48751A MA 48751 A MA48751 A MA 48751A MA 048751 A MA048751 A MA 048751A MA 48751 A MA48751 A MA 48751A MA 48751 A MA48751 A MA 48751A
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- venetoclax
- antibodies
- paradigm
- combined
- Prior art date
Links
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 title 1
- 229960001183 venetoclax Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17173712 | 2017-05-31 | ||
| PCT/EP2018/064229 WO2018220040A1 (fr) | 2017-05-31 | 2018-05-30 | Paradigme de traitement pour un traitement combiné d'anticorps anti-cd19 et de venetoclax |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA48751A true MA48751A (fr) | 2020-04-08 |
| MA48751B1 MA48751B1 (fr) | 2023-11-30 |
Family
ID=59070416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA48751A MA48751B1 (fr) | 2017-05-31 | 2018-05-30 | Paradigme de traitement d'anticorps anti-cd19 et traitement de combinaison venetoclax |
Country Status (24)
| Country | Link |
|---|---|
| EP (2) | EP4268900A3 (fr) |
| JP (2) | JP7399713B2 (fr) |
| KR (2) | KR20240117655A (fr) |
| CN (1) | CN110678201A (fr) |
| AU (1) | AU2018276384A1 (fr) |
| BR (1) | BR112019025034A2 (fr) |
| CA (1) | CA3062400A1 (fr) |
| DK (1) | DK3630177T5 (fr) |
| ES (1) | ES2961940T3 (fr) |
| FI (1) | FI3630177T3 (fr) |
| HR (1) | HRP20231229T1 (fr) |
| HU (1) | HUE063119T2 (fr) |
| IL (2) | IL270855B2 (fr) |
| LT (1) | LT3630177T (fr) |
| MA (1) | MA48751B1 (fr) |
| MD (1) | MD3630177T2 (fr) |
| MX (2) | MX2019014330A (fr) |
| PL (1) | PL3630177T3 (fr) |
| PT (1) | PT3630177T (fr) |
| RS (1) | RS64746B1 (fr) |
| SG (1) | SG11201909715VA (fr) |
| SI (1) | SI3630177T1 (fr) |
| WO (1) | WO2018220040A1 (fr) |
| ZA (1) | ZA201907369B (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3203587A1 (fr) * | 2020-11-30 | 2022-06-02 | Incyte Corporation | Polytherapie faisant appel a un anticorps anti-cd19 et a du parsaclisib |
| WO2022115120A1 (fr) * | 2020-11-30 | 2022-06-02 | Incyte Corporation | Polythérapie comprenant un anticorps anti-cd19 et le parsaclisib |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2534639C (fr) | 2003-07-31 | 2013-07-30 | Immunomedics, Inc. | Anticorps anti-cd19 |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| EP1899379B1 (fr) | 2005-06-20 | 2018-04-11 | E. R. Squibb & Sons, L.L.C. | Anticorps cd19 et utilisations |
| EP2270050B1 (fr) | 2005-12-30 | 2013-06-05 | Merck Patent GmbH | Anticorps anti-CD19 avec une immunogénicité réduite |
| ES2402591T3 (es) | 2006-08-14 | 2013-05-07 | Xencor Inc. | Anticuerpos optimizados que seleccionan como diana CD19 |
| EP2066349B1 (fr) | 2006-09-08 | 2012-03-28 | MedImmune, LLC | Anticorps anti-cd19 humanises et leur utilisation dans le traitement des tumeurs, de la transplantation et des maladies auto-immunes |
| LT2211904T (lt) | 2007-10-19 | 2016-11-25 | Seattle Genetics, Inc. | Cd19 surišantys agentai ir jų panaudojimas |
| US8679492B2 (en) | 2009-02-23 | 2014-03-25 | Glenmark Pharmaceuticals S.A. | Humanized antibodies that bind to CD19 and their uses |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| HUE058855T2 (hu) * | 2011-08-16 | 2022-09-28 | Morphosys Ag | Kombinációs terápia, CD19 elleni ellenanyag és purinanalóg alkalmazásával |
| KR20200058583A (ko) * | 2011-08-16 | 2020-05-27 | 모르포시스 아게 | 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법 |
| WO2017032679A1 (fr) | 2015-08-21 | 2017-03-02 | Morphosys Ag | Combinaisons et utilisations de celles-ci |
| LT3532098T (lt) * | 2016-10-28 | 2021-06-25 | Morphosys Ag | Anti cd19 antikūno derinys su bcl-2 inhibitoriumi, ir jo naudojimas |
-
2018
- 2018-05-30 AU AU2018276384A patent/AU2018276384A1/en active Pending
- 2018-05-30 HU HUE18728153A patent/HUE063119T2/hu unknown
- 2018-05-30 CN CN201880035726.5A patent/CN110678201A/zh active Pending
- 2018-05-30 PL PL18728153.0T patent/PL3630177T3/pl unknown
- 2018-05-30 KR KR1020247024908A patent/KR20240117655A/ko not_active Application Discontinuation
- 2018-05-30 MX MX2019014330A patent/MX2019014330A/es unknown
- 2018-05-30 SG SG11201909715V patent/SG11201909715VA/en unknown
- 2018-05-30 MD MDE20200316T patent/MD3630177T2/ro unknown
- 2018-05-30 IL IL270855A patent/IL270855B2/en unknown
- 2018-05-30 WO PCT/EP2018/064229 patent/WO2018220040A1/fr active Application Filing
- 2018-05-30 SI SI201831004T patent/SI3630177T1/sl unknown
- 2018-05-30 EP EP23190328.7A patent/EP4268900A3/fr active Pending
- 2018-05-30 LT LTEPPCT/EP2018/064229T patent/LT3630177T/lt unknown
- 2018-05-30 BR BR112019025034-4A patent/BR112019025034A2/pt unknown
- 2018-05-30 IL IL297461A patent/IL297461B2/en unknown
- 2018-05-30 JP JP2019565795A patent/JP7399713B2/ja active Active
- 2018-05-30 RS RS20230937A patent/RS64746B1/sr unknown
- 2018-05-30 KR KR1020197037961A patent/KR20200010472A/ko active Application Filing
- 2018-05-30 EP EP18728153.0A patent/EP3630177B1/fr active Active
- 2018-05-30 FI FIEP18728153.0T patent/FI3630177T3/fi active
- 2018-05-30 ES ES18728153T patent/ES2961940T3/es active Active
- 2018-05-30 MA MA48751A patent/MA48751B1/fr unknown
- 2018-05-30 DK DK18728153.0T patent/DK3630177T5/da active
- 2018-05-30 PT PT187281530T patent/PT3630177T/pt unknown
- 2018-05-30 CA CA3062400A patent/CA3062400A1/fr active Pending
- 2018-05-30 HR HRP20231229TT patent/HRP20231229T1/hr unknown
-
2019
- 2019-11-06 ZA ZA2019/07369A patent/ZA201907369B/en unknown
- 2019-11-28 MX MX2023013228A patent/MX2023013228A/es unknown
-
2023
- 2023-12-06 JP JP2023205931A patent/JP2024028865A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51631A (fr) | Anticorps anti-pd1 et méthodes de traitement | |
| MA55697A (fr) | Molécules d'anticorps pour le traitement du cancer | |
| MA47208A (fr) | Procédés de traitement du cancer à l'aide d'anticorps anti-pd-1 | |
| MA52742A (fr) | Anticorps bispécifiques dll3-cd3 | |
| MA49394A (fr) | Procédé de fabrication d'anticorps bispécifiques, anticorps bispécifiques et utilisation thérapeutique desdits anticorps | |
| MA50359A (fr) | Anticorps anti-cd38 et procédés d'utilisation | |
| MA50957A (fr) | Anticorps anti-tigit et leurs méthodes d'utilisation | |
| MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
| MA52962A (fr) | Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1 | |
| MA50505A (fr) | Anticorps 2 + 1 bispécifiques (contorsbodies) | |
| MA51677A (fr) | Méthodes de traitement du cancer à l'aide d'anticorps anti-pd-1 | |
| MA43197A (fr) | Constructions d'anticorps bispécifiques pour cdh3 et cd3 | |
| MA47604A (fr) | Anticorps anti-pd-1 pour le traitement du cancer du poumon | |
| MA42243A (fr) | Anticorps de facteur xi et méthodes d'utilisation | |
| MA50956A (fr) | Anticorps anti-cd137 et procédés d'utilisation correspondants | |
| MA52789A (fr) | Méthodes de traitement du cancer avec des anticorps anti-pd-1 | |
| MA47719A (fr) | Esketamine pour le traitement de la dépression | |
| MA55629A (fr) | Compositions d'anticorps pour le traitement de tumeurs | |
| MA40682A (fr) | Anticorps anti-ox40 et procédés d'utilisation correspondants | |
| MA43982A (fr) | Anticorps anti-tnf, compositions, méthodes et utilisation pour le traitement ou la prévention du diabète de type 1 | |
| MA52657A (fr) | Anticorps spécifiques d'axl pour le traitement du cancer | |
| MA50943A (fr) | Anticorps anti-liv1 humanisés pour le traitement du cancer du sein | |
| MA52366A (fr) | Anticorps anti-tl1a optimisés | |
| MA42657A (fr) | Anticorps inhibiteurs anti-pcsk9 destinés au traitement des patients atteints d'hyperlipidémie subissant une aphérèse de lipoprotéines | |
| MA46842A (fr) | Méthodes de traitement de l'obésité au moyen d'anticorps anti-angptl8 |